USA flag logo/image

An Official Website of the United States Government

Innovative molecular cytogenetic techniques for early leukemia/lymphoma…

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
75510
Program Year/Program:
2005 / SBIR
Agency Tracking Number:
CA117161
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Chromotrax, Inc.
Chromotrax, Inc. 2000 N 14Th St, Ste 530 Arlington, VA 22201 0250
View profile »
Woman-Owned: Yes
Minority-Owned: Yes
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2005
Title: Innovative molecular cytogenetic techniques for early leukemia/lymphoma detection
Agency: HHS
Contract: 1R43CA117161-01
Award Amount: $231,815.00
 

Abstract:

DESCRIPTION (provided by applicant): We propose an innovative approach combining two separate, novel techniques to greatly enhance accurate detection of leukemia or lymphoma cells, which can be used ultimately for diagnostics and early detection of minimal residual disease (MRD) in bone marrow, lymph nodes, and peripheral blood. The novel techniques of our approach are: (1) A two-step method to generate repetitive sequences depleted DMA probes. The method includes subtracting hybridized biotin-labeled repetitive-sequence DNA complex with phenol and chloroform and a second subtraction using avidin labeled magnetic beads. The unique sequences are then recovered using our dual unique sequence primers. (2) A novel technique of hybridizing chromosomes in suspension with fluorescently-labeled repetitive sequences depleted DNA probes, in combination with flow cytometric analysis or magnetic sorting, in order to sensitively, precisely and rapidly quantify leukemia or lymphoma-related chromosome translocations and rearrangements. Morphologic examination has a detection sensitivity of 1 in 100. PCR technique is very sensitive, but lack of accurate quantitation still is a problem. By contrast, hybridizing chromosomes in suspension has a potential sensitivity of 1 in 1,000,000. We propose to use leukemia as a model to demonstrate solution hybridization technique in conjunction with repetitive sequences depleted DNA probes as a sensitive and specific technique for accurate detection of MRD. Early detection of MRD will increase patient survival and profoundly impact cancer patient management.

Principal Investigator:

Joe N. Lucas
7035583400
LUCAS@CHROMOTRAX.COM

Business Contact:


7035583400
Small Business Information at Submission:

Chromotrax, Inc.
Chromotrax, Inc. 2000 N 14Th St, Ste 530 Arlington, VA 22201

EIN/Tax ID: 542021057
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No